Depeng P. Li

No. 99 West Huaihai Road
Xuzhou, 221002, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 58 publications

Allo-HSCT Might Improve Long-Term Survival in Patients with CD56-Positive AML.

Allo-HSCT Might Improve Long-Term Survival in Patients with CD56-Positive AML.

Journal: Journal of blood medicine

Published: February 08, 2026

Late phase transfusion after CAR T therapy is associated with persistent hematotoxicity and non-relapse mortality in multiple myeloma: a post hoc analysis.

Late phase transfusion after CAR T therapy is associated with persistent hematotoxicity and non-relapse mortality in multiple myeloma: a post hoc analysis.

Journal: BMC medicine

Published: February 07, 2026

Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease.

Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease.

Journal: Blood

Published: February 03, 2026

High FCRL5 expression predicts poor treatment response and survival in newly diagnosed multiple myeloma: a retrospective study.

High FCRL5 expression predicts poor treatment response and survival in newly diagnosed multiple myeloma: a retrospective study.

Journal: Frontiers in oncology

Published: December 10, 2025

The impact of antibiotic use on outcomes of relapsed/refractory multiple myeloma patients treated with CAR-T therapy.

The impact of antibiotic use on outcomes of relapsed/refractory multiple myeloma patients treated with CAR-T therapy.

Journal: Frontiers in immunology

Published: January 24, 2025

Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial.

Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial.

Journal: The Lancet. Haematology

Published: November 30, 2024

Lymphocyte/monocyte to lactate dehydrogenase ratio prior to lymphodepletion impact the outcomes of patients with diffused large B cell lymphoma undergoing CAR-T cell therapy.

Lymphocyte/monocyte to lactate dehydrogenase ratio prior to lymphodepletion impact the outcomes of patients with diffused large B cell lymphoma undergoing CAR-T cell therapy.

Journal: Cancer immunology, immunotherapy : CII

Published: November 20, 2024

Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma.

Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma.

Journal: Blood

Published: August 19, 2024

Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma.

Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma.

Journal: Clinical and experimental medicine

Published: July 07, 2024

Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti-BCMA CAR T-cell-based therapy.

Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti-BCMA CAR T-cell-based therapy.

Journal: American journal of hematology

Published: May 16, 2024

Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial.

Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial.

Journal: The Lancet. Haematology

Published: March 10, 2024

Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial.

Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial.

Journal: Nature communications

Published: January 24, 2024

Showing 1-12 of 58

Last Updated: 09/26/2026